Drabner B, Guzmán C A
Vaccine Research Group, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, D-38124, Braunschweig, Germany.
Biomol Eng. 2001 Mar;17(3):75-82. doi: 10.1016/s1389-0344(00)00072-1.
There is an increasing need for novel vaccines able to stimulate efficient and long-lasting responses, which have also low production costs. To confer protective immunity following vaccination, the adequate type of response should be elicited. Vaccines based on attenuated bacterial carriers have contained production and delivery costs, and are able to stimulate more potent immune responses than non-replicating formulations. The improved knowledge on carrier physiology and host response, the availability of different mutants and highly sophisticated expression tools, and the possibility of co-administering modulators enable to trigger predictable responses according to the specific needs. Recent studies support the use of attenuated bacteria not only as conventional carriers, but also as a delivery system for DNA vaccines against infectious agents and tumors. In this review we discuss the most widely used bacterial carrier systems for either antigens or nucleic acid vaccines, and the strategies which have been successfully exploited to modulate the immune responses elicited.
对能够激发高效且持久反应、生产成本又低的新型疫苗的需求日益增加。为了在接种疫苗后赋予保护性免疫，应引发适当类型的反应。基于减毒细菌载体的疫苗降低了生产和递送成本，并且比非复制型制剂能够激发更强有力的免疫反应。对载体生理学和宿主反应的深入了解、不同突变体和高度复杂表达工具的可得性，以及共同施用调节剂的可能性，使得能够根据特定需求触发可预测的反应。最近的研究支持将减毒细菌不仅用作传统载体，还用作针对传染病原体和肿瘤的DNA疫苗的递送系统。在这篇综述中，我们讨论了用于抗原或核酸疫苗的最广泛使用的细菌载体系统，以及已成功用于调节所引发免疫反应的策略。
